New inovative pharmacogenetic testing available at St. Catherine.
American company OneOme, co-founded with Mayo Clinic, announced today that they are partnering with St. Catherine Specialty Hospital, a European Center of Excellence, to bring innovative, actionable pharmacogenetic (PGx) testing to patients. St. Catherine will offer its patients the OneOme RightMed® comprehensive test, a PGx test that uses a person’s DNA to predict their response to hundreds of medications.
Because medications affect everyone differently, determining the right prescription can be a challenge for your doctor. A drug that’s effective for one person may have no effect for another person, cause a partial response in someone else, or result in undesirable side effects for another. With medication response testing, we can unlock information about how specific drugs may affect you, based on your DNA. When you take a medication, your body’s response is determined by many factors including your gender, weight, age, diet, other medications, any medical conditions, and exposure to environmental agents such as cigarette smoke. Your genetic makeup also can have a major influence. In fact, genetic factors can account for up to 95% of how you respond to medications. Depending on your genes, your body may break down a drug too slowly or too quickly. If you metabolize a drug too slowly, you may be exposed to too much of it, which may result in side effects. If you metabolize a drug too quickly, you may not get enough of it to have any effect at all.
Using the RightMed test results and OneOme’s supporting technology, physicians at St. Catherine may prescribe more effective medications with fewer side effects.
The RightMed test covers 27 genes and hundreds of medications used to treat 30 medical conditions, including cancer, pain, psychiatric disorders, and cardiovascular disease. The comprehensive coverage of the RightMed test provides PGx results that can be used for years to come when treating these medical conditions.
“St. Catherine is well regarded across the globe for its high quality of care and for its innovative diagnostic and personalized treatment strategies,” said Paul Owen, CEO of OneOme. “We look forward to further enhancing St. Catherine’s level of care with the RightMed solution by helping its physicians optimize treatment strategies.”
“We selected the RightMed test because of its scientific rigor and because it covers more genes and medications than any other product we identified,” said Dr. Dragan Primorac, president of the Board of Trustees at St. Catherine. “We are particularly excited to provide clinical insights to guide the enhancement of OneOme’s solution and for the potential the test holds in optimizing pain management.”
St. Catherine and OneOme are also collaborating on a research study to evaluate pain management treatments for lower back pain.